A Digital Health Weight Loss Program in 250,000 Individuals

Abstract

Importance. Obesity is a worsening epidemic worldwide. Effective and accessible weight loss programs to combat obesity on a large scale are warranted, but a need for frequent face-to-face care might impose a limitation. Objective. To evaluate whether individuals following a weight loss program based on a mobile application, wireless scale, and nutritional program but no face-to-face care can achieve clinically significant weight loss in a large cohort. Design. Retrospective observational analysis. Setting. China from October 2016 to December 2017. Participants. Mobile application users with a minimum of 2 weights (baseline and ≥35 days). Intervention. A commercial (Weijian Technologies) weight loss program consisting of a dietary replacement, self-monitoring using a wireless home scale, and frequent guidance via mobile application. Main Outcome. Mean weight change around 42, 60, 90, and 120 days after program initiation with subgroup analysis by gender, age, and frequency of use. Results. 251,718 individuals, with a mean age of 37.3 years (SD: 9.86) (79% female), were included with a mean weight loss of 4.3 kg (CI: ±0.02) and a mean follow-up of 120 days (SD: 76.8 days). Mean weight loss at 42, 60, 90, and 120 d was 4.1 kg (CI: ±0.02), 4.9 kg (CI: ±0.02), 5.6 kg (CI: ±0.03), and 5.4 kg (CI: ±0.04), respectively. At 120 d, 62.7% of participants had lost at least 5% of their initial weight. Both genders and all usage frequency tertiles showed statistically significant weight loss from baseline at each interval (P<0.001), and this loss was greater in men than in women (120 d: 6.5 vs. 5.2 kg; P<0.001). The frequency of recording (categorized as high-, medium-, or low-frequency users) was associated with greater weight loss when comparing high, medium, and low tertile use groups at all time intervals investigated (e.g., 120 d: −8.6, −5.6, and −2.2 kg, respectively; P<0.001). Conclusions. People following a commercially available hybrid weight loss program using a mobile application, wireless scale, and nutritional program without face-to-face interaction on average achieved clinically significant short- and midterm weight loss. These results support the implementation of comparable technologies for weight control in a large population.

Assessment of health-related quality of life among obese patients in Abha, Saudi Arabia

“…The increase in obesity rate and frequency are related to many causes like socioeconomic status, married life, and other lifestyle factors. [ 2 3 4 5 6 7 ]…”

Efficacy of Remote Monitoring of Overweight Patients with Connected Health Platform

“…As frequent face-to-face care might impose a limitation for accessible programs, Senecal et al demonstrated that a weight loss program based on a mobile application, wireless scale, and nutritional program but no face-to-face care, can achieve clinically significant short-and midterm weight loss [10]. Weighing everyday matters.…”

Internet-based platform for a low-calorie dietary intervention involving prepackaged food for weight loss in overweight and obese individuals in China: protocol for a randomised controlled trial

“…The results demonstrated that at 120 days after programme initiation, 62.7% of participants had lost at least 5% of their initial weight. 10 However, further investigations of the effects of this type of intervention on body composition, fat distribution and improvements in metabolic issues, such as abnormal blood pressure and insulin resistance, warrant further investigation.…”

“…The MetaWell programme (Weijian Technologies, Hangzhou, China) is a commercial weight loss programme in China that integrates prepackaged food, online guidance and a wireless home scale and has been proven to be effective in a previous retrospective study. The results demonstrated that at 120 days after programme initiation, 62.7% of participants had lost at least 5% of their initial weight 10. However, further investigations of the effects of this type of intervention on body composition, fat distribution and improvements in metabolic issues, such as abnormal blood pressure and insulin resistance, warrant further investigation.…”